Human Tetherin Exerts Strong Selection Pressure on the HIV-1 Group N Vpu Protein
暂无分享,去创建一个
G. Learn | F. Kirchhoff | B. Hahn | M. Peeters | F. Bibollet-Ruche | J. Fritz | O. Fackler | D. Sauter | Daniel Unterweger | E. Barker | Silvia F. Kluge | S. Usmani | M. Moll | M. Vogl | Anke Heigele | Elisabeth Hermkes | Joëlle V. Fritz
[1] Lamar B. Fleming,et al. Vpu-Deficient HIV Strains Stimulate Innate Immune Signaling Responses in Target Cells , 2012, Journal of Virology.
[2] M. McElrath,et al. Vpu Mediates Depletion of Interferon Regulatory Factor 3 during HIV Infection by a Lysosome-Dependent Mechanism , 2012, Journal of Virology.
[3] S. Neil,et al. A Cytoplasmic Tail Determinant in HIV-1 Vpu Mediates Targeting of Tetherin for Endosomal Degradation and Counteracts Interferon-Induced Restriction , 2012, PLoS pathogens.
[4] F. Kirchhoff,et al. HIV-1 Group P is unable to antagonize human tetherin by Vpu, Env or Nef , 2011, Retrovirology.
[5] G. Towers,et al. Analysis of the human immunodeficiency virus type 1 M group Vpu domains involved in antagonizing tetherin , 2011, The Journal of general virology.
[6] C. Delaugerre,et al. HIV-1 group N: travelling beyond Cameroon , 2011, The Lancet.
[7] P. Cannon,et al. Lack of adaptation to human tetherin in HIV-1 Group O and P , 2011, Retrovirology.
[8] S. Neil,et al. Separable Determinants of Subcellular Localization and Interaction Account for the Inability of Group O HIV-1 Vpu To Counteract Tetherin , 2011, Journal of Virology.
[9] J. Fritz,et al. HIV-1 Vpu Blocks Recycling and Biosynthetic Transport of the Intrinsic Immunity Factor CD317/Tetherin To Overcome the Virion Release Restriction , 2011, mBio.
[10] L. Montaner,et al. Evidence for the innate immune response as a correlate of protection in human immunodeficiency virus (HIV)‐1 highly exposed seronegative subjects (HESN) , 2011, Clinical and experimental immunology.
[11] J. Fritz,et al. β-TrCP is dispensable for Vpu's ability to overcome the CD317/Tetherin-imposed restriction to HIV-1 release , 2011, Retrovirology.
[12] E. Campbell,et al. Degranulation of natural killer cells following interaction with HIV-1-infected cells is hindered by downmodulation of NTB-A by Vpu. , 2010, Cell host & microbe.
[13] C. Brennan,et al. Confirmation of Putative HIV-1 Group P in Cameroon , 2010, Journal of Virology.
[14] Takeshi Yoshida,et al. Identification of Amino Acids in the Human Tetherin Transmembrane Domain Responsible for HIV-1 Vpu Interaction and Susceptibility , 2010, Journal of Virology.
[15] S. Neil,et al. Determinants of Tetherin Antagonism in the Transmembrane Domain of the Human Immunodeficiency Virus Type 1 Vpu Protein , 2010, Journal of Virology.
[16] K. Strebel,et al. HIV-1 Vpu targets cell surface markers CD4 and BST-2 through distinct mechanisms. , 2010, Molecular aspects of medicine.
[17] Mustapha Samrakandi,et al. Dual-color click beetle luciferase heteroprotein fragment complementation assays. , 2010, Chemistry & biology.
[18] M. Moll,et al. Inhibition of lipid antigen presentation in dendritic cells by HIV-1 Vpu interference with CD1d recycling from endosomal compartments. , 2010, Blood.
[19] Rajendra Singh,et al. BST-2/tetherin: a new component of the innate immune response to enveloped viruses. , 2010, Trends in microbiology.
[20] P. Sharp,et al. The evolution of HIV-1 and the origin of AIDS , 2010, Philosophical Transactions of the Royal Society B: Biological Sciences.
[21] F. Kirchhoff. Immune evasion and counteraction of restriction factors by HIV-1 and other primate lentiviruses. , 2010, Cell host & microbe.
[22] Michael Emerman,et al. Ancient Adaptive Evolution of Tetherin Shaped the Functions of Vpu and Nef in Human Immunodeficiency Virus and Primate Lentiviruses , 2010, Journal of Virology.
[23] F. Kirchhoff,et al. Tetherin: Holding On and Letting Go , 2010, Cell.
[24] Andrew A McCarthy,et al. Structural basis of HIV-1 tethering to membranes by the BST-2/tetherin ectodomain. , 2010, Cell host & microbe.
[25] É. Cohen,et al. Antagonism of Tetherin Restriction of HIV-1 Release by Vpu Involves Binding and Sequestration of the Restriction Factor in a Perinuclear Compartment , 2010, PLoS pathogens.
[26] O. Gascuel,et al. New algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance of PhyML 3.0. , 2010, Systematic biology.
[27] P. Cannon,et al. Anti-tetherin activities in Vpu-expressing primate lentiviruses , 2010, Retrovirology.
[28] C. McArthur,et al. Four new HIV-1 group N isolates from Cameroon: Prevalence continues to be low. , 2010, AIDS research and human retroviruses.
[29] F. Kirchhoff,et al. Vpu serine 52 dependent counteraction of tetherin is required for HIV-1 replication in macrophages, but not in ex vivo human lymphoid tissue , 2010, Retrovirology.
[30] Ravindra K. Gupta,et al. A tail of Tetherin: how pandemic HIV-1 conquered the world. , 2009, Cell host & microbe.
[31] G. Learn,et al. Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains. , 2009, Cell host & microbe.
[32] Marc C. Johnson,et al. Tetherin Inhibits HIV-1 Release by Directly Tethering Virions to Cells , 2009, Cell.
[33] Jean-Yves Nau,et al. [A new human immunodeficiency virus derived from gorillas]. , 2009, Revue medicale suisse.
[34] J. Luban,et al. HIV-1 Vpu Neutralizes the Antiviral Factor Tetherin/BST-2 by Binding It and Directing Its Beta-TrCP2-Dependent Degradation , 2009, PLoS pathogens.
[35] Marc C. Johnson,et al. Nef proteins from simian immunodeficiency viruses are tetherin antagonists. , 2009, Cell host & microbe.
[36] A. Moses,et al. Vpu Directs the Degradation of the Human Immunodeficiency Virus Restriction Factor BST-2/Tetherin via a βTrCP-Dependent Mechanism , 2009, Journal of Virology.
[37] R. Benarous,et al. Vpu Antagonizes BST-2–Mediated Restriction of HIV-1 Release via β-TrCP and Endo-Lysosomal Trafficking , 2009, PLoS pathogens.
[38] S. Westmoreland,et al. Species-Specific Activity of SIV Nef and HIV-1 Vpu in Overcoming Restriction by Tetherin/BST2 , 2009, PLoS pathogens.
[39] D. Pillay,et al. Mutation of a Single Residue Renders Human Tetherin Resistant to HIV-1 Vpu-Mediated Depletion , 2009, PLoS pathogens.
[40] P. Bieniasz,et al. Species-Specific Activity of HIV-1 Vpu and Positive Selection of Tetherin Transmembrane Domain Variants , 2009, PLoS pathogens.
[41] Michael Emerman,et al. HIV-1 accessory proteins--ensuring viral survival in a hostile environment. , 2008, Cell host & microbe.
[42] Marc C. Johnson,et al. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. , 2008, Cell host & microbe.
[43] P. Bieniasz,et al. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu , 2008, Nature.
[44] Rodrigo Lopez,et al. Clustal W and Clustal X version 2.0 , 2007, Bioinform..
[45] F. Kirchhoff,et al. Nef-Mediated Enhancement of Virion Infectivity and Stimulation of Viral Replication Are Fundamental Properties of Primate Lentiviruses , 2007, Journal of Virology.
[46] L. Wain,et al. Chimpanzee Reservoirs of Pandemic and Nonpandemic HIV-1 , 2006, Science.
[47] Hui Li,et al. Nef-Mediated Suppression of T Cell Activation Was Lost in a Lentiviral Lineage that Gave Rise to HIV-1 , 2006, Cell.
[48] C. McArthur,et al. HIV-1 Group N: evidence of ongoing transmission in Cameroon. , 2006, AIDS research and human retroviruses.
[49] C. Brennan,et al. Identification of HIV type 1 group N infections in a husband and wife in Cameroon: viral genome sequences provide evidence for horizontal transmission. , 2006, AIDS research and human retroviruses.
[50] David Posada,et al. ProtTest: selection of best-fit models of protein evolution , 2005, Bioinform..
[51] C. McArthur,et al. Identification and genomic sequence of an HIV type 1 group N isolate from Cameroon. , 2004, AIDS research and human retroviruses.
[52] François Simon,et al. Phylogenetic characteristics of three new HIV-1 N strains and implications for the origin of group N , 2004, AIDS.
[53] George Banting,et al. Bst‐2/HM1.24 Is a Raft‐Associated Apical Membrane Protein with an Unusual Topology , 2003, Traffic.
[54] J. Kappes,et al. Emergence of Resistant Human Immunodeficiency Virus Type 1 in Patients Receiving Fusion Inhibitor (T-20) Monotherapy , 2002, Antimicrobial Agents and Chemotherapy.
[55] J. Kappes,et al. Sensitivity of Human Immunodeficiency Virus Type 1 to the Fusion Inhibitor T-20 Is Modulated by Coreceptor Specificity Defined by the V3 Loop of gp120 , 2000, Journal of Virology.
[56] K. Lole,et al. Full-Length Human Immunodeficiency Virus Type 1 Genomes from Subtype C-Infected Seroconverters in India, with Evidence of Intersubtype Recombination , 1999, Journal of Virology.
[57] F. Brun-Vézinet,et al. Identification of a new human immunodeficiency virus type 1 distinct from group M and group O , 1998, Nature Medicine.
[58] B. Chesebro,et al. Effects of CCR5 and CD4 Cell Surface Concentrations on Infections by Macrophagetropic Isolates of Human Immunodeficiency Virus Type 1 , 1998, Journal of Virology.
[59] D. Thomas,et al. A novel human WD protein, h-beta TrCp, that interacts with HIV-1 Vpu connects CD4 to the ER degradation pathway through an F-box motif. , 1998, Molecular cell.
[60] D. T. Jones,et al. A new approach to protein fold recognition , 1992, Nature.